4.6 Review

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms

Journal

CANCERS
Volume 13, Issue 9, Pages -

Publisher

MDPI
DOI: 10.3390/cancers13092120

Keywords

myelodysplastic; myeloproliferative neoplasms; cytogenetics; molecular landscape; gene mutations

Categories

Funding

  1. Instituto de Salud Carlos III, Ministerio de Economia y Competividad, Spain [PI/ 17/0575]
  2. Generalitat de Catalunya [2017 SGR288]
  3. CERCA Programme/Generalitat de Catalunya
  4. Fundacio Internacional Josep Carreras
  5. la Caixa Foundation

Ask authors/readers for more resources

Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are characterized by overlapping features from both myelodysplastic syndromes and myeloproliferative neoplasms. The majority of patients with this disease have mutations in common myeloid neoplasm genes, which play a role in clinical heterogeneity and evolution.
Simple Summary: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid neoplasms characterized, at the time of their presentation, by the simultaneous presence of both myelodysplastic and myeloproliferative features. In MDS/MPN, the karyotype is often normal but mutations in genes that are common across myeloid neoplasms can be detected in a high proportion of cases by targeted sequencing. In this review, we intend to summarize the main genetic findings across all MDS/MPN overlap syndromes and discuss their relevance in the management of patients. Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are myeloid neoplasms characterized by the presentation of overlapping features from both myelodysplastic syndromes and myeloproliferative neoplasms. Although the classification of MDS/MPN relies largely on clinical features and peripheral blood and bone marrow morphology, studies have demonstrated that a large proportion of patients (similar to 90%) with this disease harbor somatic mutations in a group of genes that are common across myeloid neoplasms. These mutations play a role in the clinical heterogeneity of these diseases and their clinical evolution. Nevertheless, none of them is specific to MDS/MPN and current diagnostic criteria do not include molecular data. Even when such alterations can be helpful for differential diagnosis, they should not be used alone as proof of neoplasia because some of these mutations may also occur in healthy older people. Here, we intend to review the main genetic findings across all MDS/MPN overlap syndromes and discuss their relevance in the management of the patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available